Neck Mass Found in 45-Year-Old Man

Poll

A 45-year-old man presents with a mass in the right neck. After the biopsy is performed, what is your diagnosis?

A 45-year-old man presents with a mass in the right neck. According to the pathology slide below, what is your diagnosis?

What is your diagnosis?

A. Leiomyosarcoma
B. Desmoid tumor
C. Spindle cell lipoma
D. Squamous cell carcinoma
Recent Videos
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Expert Discusses Safety of Toripalimab in Advanced Nasopharyngeal Carcinoma
Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.
Toripalimab Yields ‘Striking’ PFS Improvement in Nasopharyngeal Carcinoma
head and neck cancer
HNSCC: Integrating Tipifarnib Into Treatment Algorithms
Andrew Cook, MD, Discussed Exciting Clinical Trials Utilizing DART and Treatment De-Escalation in HPV+ OSCC
Andrew Cook, MD, Discussed Exciting Clinical Trials Utilizing DART and Treatment De-Escalation in HPV+ OSCC
Andrew Cook, MD, on On-Going Clinical Research Efforts in the Head and Neck Cancer Space
Andrew Cook, MD, on On-Going Clinical Research Efforts in the Head and Neck Cancer Space
head and neck cancer
Tipifarnib in mHRAS HNSCC: Remaining Questions
Andrew Cook, MD, on the Potential Role of Gabapentin in Head and Neck Cancer
Andrew Cook, MD, on the Potential Role of Gabapentin in Head and Neck Cancer
Andrew Cook, MD, Discussed Outcomes with Gabapentin vs Opioids to Prevent Treatment-Related Pain in Oropharyngeal Cancer
Andrew Cook, MD, Discussed Outcomes with Gabapentin vs Opioids to Prevent Treatment-Related Pain in Oropharyngeal Cancer
Andrew Cook, MD, Discussed the Rational for Using Gabapentin to Prevent CRT-Related Pain in Oropharyngeal Cancer
Andrew Cook, MD, Discussed the Rational for Using Gabapentin to Prevent CRT-Related Pain in Oropharyngeal Cancer
head and neck cancer
HRAS Mutations in Head and Neck Cancer
Related Content
Pembrolizumab/Bevacizumab Improves Efficacy in Nasopharyngeal Carcinoma

Pembrolizumab/Bevacizumab Improves Efficacy in Nasopharyngeal Carcinoma

Tim Cortese
March 2nd 2025
Article

Pembrolizumab and bevacizumab yielded an ORR of 58.3% vs 12.5% with pembrolizumab monotherapy in patients with platinum-resistant nasopharyngeal carcinoma.

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David J. Sher, MD, MPH
September 15th 2017
Podcast

In this interview we discuss new clinical guidelines from ASTRO on the use of radiotherapy in treating oropharyngeal cancer.

Investigators will assess treatment with petosemtamab among patients with PD-L1–positive HNSCC in the phase 3 LiGeR-HN1 and LiGeR-HN2 trials.

Petosemtamab Combo Earns Breakthrough Therapy Status in PD-L1+ HNSCC

Russ Conroy
February 20th 2025
Article

Investigators will assess treatment with petosemtamab among patients with PD-L1–positive HNSCC in the phase 3 LiGeR-HN1 and LiGeR-HN2 trials.

Data support cetuximab/radiotherapy as a suitable option in carefully selected patients with HPV-negative squamous cell carcinoma of the head and neck.

Cetuximab/Radiation Improves DFS in Locally Advanced SCCHN

Russ Conroy
February 1st 2025
Article

Data support cetuximab/radiotherapy as a suitable option in carefully selected patients with HPV-negative squamous cell carcinoma of the head and neck.

Nivolumab/Cisplatin/Radiotherapy Improves DFS in Locally Advanced SCCHN

Nivolumab/Cisplatin/Radiotherapy Improves DFS in Locally Advanced SCCHN

Tim Cortese
January 9th 2025
Article

The phase 3 NIVOPOSTOP GORTEC 2018-01 trial shows that nivolumab added to radiotherapy and cisplatin had improved efficacy over SOC treatments in SCCHN.

Cisplatin/70 Gy IMRT Cemented as SOC for Nonsmoking p16+ Oropharyngeal Cancer

Cisplatin/70 Gy IMRT Cemented as SOC for Nonsmoking p16+ Oropharyngeal Cancer

Gina Mauro
September 30th 2024
Article

Experimental regimens did not cross the threshold to show superiority vs standard cisplatin plus 70 Gy radiation in those with HPV-associated oropharynx cancer.